Puma Biotechnology

2016 News Releases

Puma Biotechnology Closes $172 Million Public Offering of Common Stock

LOS ANGELES, Calif., Oct. 25, 2016 - Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, announced the closing of an underwritten public offering of 4,312,500 shares of its common stock at a price to the public of $40.00 per share. The shares of common stock issued in the offering included 562,500 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds from the offering were approximately $162 million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company.

Citigroup and J.P. Morgan acted as lead book-running managers, Credit Suisse acted as joint book-running manager and BofA Merrill Lynch acted as lead manager for the offering. Stifel acted as co-manager for the offering.

The offering was made pursuant to an automatically effective shelf registration statement filed with the Securities and Exchange Commission (SEC) on January 20, 2015. A prospectus supplement describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may be obtained by contacting Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at (800) 831-9146; J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by phone at (866) 803-9204; or Credit Suisse, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037, or by email at newyork.prospectus@credit-suisse.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Contact:
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com

Back to 2016 News Releases